ACADIA Pharmaceuticals Inc.

The momentum for this stock is not very good. ACADIA Pharmaceuticals Inc. has good growth characteristics. ACADIA Pharmaceuticals Inc. is not very popular among insiders. ACADIA Pharmaceuticals Inc. is a mediocre stock to choose.
Log in to see more information.
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and...
ACAD Fundamental Data by TradingView

News

Bank of New York Mellon Corp Grows Stock Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Bank of New York Mellon Corp Grows Stock Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Ticker Report Bank of New York Mellon Corp increased its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 4.5% in the 2nd quarter, according to its most recent 13F filing with the...\n more…

Acadia (ACAD) Up 10% Since Last Earnings Report: Can It Continue?
Acadia (ACAD) Up 10% Since Last Earnings Report: Can It Continue?

Zacks Investment Research A month has gone by since the last earnings report for Acadia Pharmaceuticals (ACAD). Shares have added about 10% in that time frame, outperforming the S&P 500.Will the recent positive trend continue...\n more…

Allspring Global Investments Holdings LLC Purchases 49,992 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Allspring Global Investments Holdings LLC Purchases 49,992 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Ticker Report Allspring Global Investments Holdings LLC raised its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 85.0% during the second quarter, according to its most recent...\n more…

Short Interest in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Decreases By 7.4%
Short Interest in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Decreases By 7.4%

Ticker Report ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) was the target of a large decrease in short interest during the month of August. As of August 15th, there was short interest totalling...\n more…

Analysts Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Target Price at $25.56
Analysts Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Target Price at $25.56

Zolmax ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) has earned an average rating of "Moderate Buy" from the sixteen analysts that are covering the company, Marketbeat reports. Five research...\n more…

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Average Recommendation of "Moderate Buy" from Brokerages
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Average Recommendation of "Moderate Buy" from Brokerages

Ticker Report Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) have been given a consensus rating of "Moderate Buy" by the sixteen research firms that are currently covering the firm...\n more…